ArticleRheumatology (Oxford, England)2019
Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study.
Article in Rheumatology (Oxford, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Value of Literature Review to Inform Development and Use of Biologics in Juvenile Idiopathic Arthritis.Frontiers in pediatrics · 2022Pooled it
- Clinical features and the impact of MEFV Variants in pediatric non-infectious uveitis: a retrospective single-center study.Clinical rheumatology · 2026Article
- Serological biomarkers of JIA-associated uveitis: ANA titers, ANA AC-30 staining pattern and prefoldin 5 antibodies.Arthritis research & therapy · 2026Article
- Clinical characteristics and factors associated with uveitis in juvenile idiopathic arthritis: a long-term single-center experience.International ophthalmology · 2026Article
- Novel advances in juvenile idiopathic arthritis associated uveitis.Arthritis research & therapy · 2026Review
- Advances in tumor necrosis factor-α inhibitors for the treatment of juvenile idiopathic arthritis-associated uveitis.Frontiers in immunology · 2026Review
- Ocular complications in pediatric non-infectious anterior uveitis in long-term follow-up: population-based cohort study.Journal of ophthalmic inflammation and infection · 2025Article
- Predictors of lack of response to methotrexate in juvenile idiopathic arthritis associated uveitis.Rheumatology (Oxford, England) · 2025Article
- Ocular involvement and visual prognosis in juvenile idiopathic arthritis associated uveitis.International journal of ophthalmology · 2025Article
- Clinical Features and Risk Factors of Uveitis in Korean Children with Juvenile Idiopathic Arthritis: A Retrospective Cohort Study.Journal of clinical medicine · 2023Article
- Improved clinical outcomes in patients with juvenile idiopathic arthritis associated uveitis in the last decade.Acta ophthalmologica · 2022Article
- Uveitis in Children and Adolescents.Rheumatic diseases clinics of North America · 2021Review
- Occurrence and Risk Factors for Macular Edema in Patients with Juvenile Idiopathic Arthritis-Associated Uveitis.Journal of clinical medicine · 2021Article
- Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab.Pediatric rheumatology online journal · 2021Article
- Long-term outcomes and disease course of children with juvenile idiopathic arthritis in the ReACCh-Out cohort: a two-centre experience.Rheumatology (Oxford, England) · 2020Article
- Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany.Arthritis research & therapy · 2020Article
- Improving quick and accurate diagnosis of childhood JIA-uveitis from a pediatric rheumatology perspective.Expert review of ophthalmology · 2020Article
- [New therapy approaches, better outcomes? : Results from inception cohorts for patients with juvenile idiopathic arthritis].Zeitschrift fur Rheumatologie · 2019Review
- Update on the management of uveitis in children: an overview for the clinician.Expert review of ophthalmology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo define predictors for the 2-year outcome in terms of achieving inactivity, subsequent uveitis reactivation and occurrence of uveitis-related complications of JIA-associated uveitis.
methodsDemographic and clinical parameters and serum samples of JIA-associated uveitis patients enrolled in ICON at ⩽1 year of JIA diagnosis were collected at study enrolment, every 3 months during the first year and subsequently every 6 months. Predictors for the 2-year outcome were evaluated by linear mixed models.
resultsOf 954 JIA patients included, uveitis occurred in 106 up to the first 2-year follow-up, with 98 of them having complete ophthalmological documentation. In 81.8% and 80.0% of patients, uveitis inactivity was achieved at the 1- and 2-year follow-up after uveitis onset, respectively. JIA onset after the age of 5 years, no use of topical corticosteroids, and adalimumab treatment were significantly associated with an inactive uveitis for at least 6 months (n = 57). Correlates for subsequent uveitis reactivation (n = 16, 30.2%) were age at uveitis onset ⩽5 years and active disease (clinical Juvenile Arthritis Disease Activity Score >4.5). Uveitis-related complications were present in 29.8% of patients at first uveitis documentation and in 30.7% and 32.8% at 1- and 2-year follow-up, respectively. Older age at JIA onset, short duration between JIA and uveitis onset, high anterior chamber (AC) cell grades, poor visual acuity, and topical steroid use at first uveitis documentation correlated with uveitis-related complications.
conclusionIn addition to demographic risk factors, JIA disease and uveitis activity scores and adalimumab are significant predictors for the 2-year outcome of JIA-associated uveitis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.